title: Increased cortisol responsivity to adrenocorticotropic hormone and low plasma levels of interleukin-1 receptor antagonist in women with functional hypothalamic amenorrhea.
abstract: OBJECTIVE
  To assess the hypothalamic-pituitary-adrenal (HPA) axis at all levels, to determine the origin of the previously reported hypercortisolism in patients with functional hypothalamic amenorrhea. A secondary aim was to evaluate factors outside the central nervous system which are known to affect the HPA axis, i.e., circulating levels of interleukin-6 (IL-6), interleukin-1 receptor antagonist (IL-1Ra), and fat mass-adjusted leptin levels, in patients with functional hypothalamic amenorrhea and healthy controls.
  
  
  METHODS
  Cross-sectional study.
  
  
  METHODS
  Umeå University Hospital, Umeå, Sweden.
  
  
  METHODS
  Fifteen subjects with hypothalamic amenorrhea, and 14 age- and weight-matched controls.
  
  
  METHODS
  None.
  
  
  METHODS
  We collected blood samples four times during a 24-hour interval for analysis of cortisol, leptin, IL-1Ra, and IL-6 levels. We performed a low-dose oral dexamethasone test and a low-dose ACTH test. We measured body-fat percentage using a dual-energy X-ray absorptiometer.
  
  
  RESULTS
  Patients with hypothalamic amenorrhea had increased diurnal cortisol levels (P<.001). The cortisol response to intravenous low-dose ACTH was increased in functional hypothalamic amenorrhea patients compared to control subjects (P<.01), but they had similar rates of dexamethasone suppression. Patients with hypothalamic amenorrhea also had decreased diurnal leptin (P<.05), and decreased diurnal IL-1Ra levels (P<.05), compared to controls. Body-fat percentage was the main predictor of leptin levels.
  
  
  CONCLUSIONS
  The present study suggests novel links for the development of functional hypothalamic amenorrhea, including increased adrenal responsiveness and impairments in proinflammatory cytokine pathways.
authors.affiliation: Department of Women's and Children's Health, Uppsala University Hospital, Uppsala, Sweden.
authors.forename: Magnus S
authors.initials: MS
authors.lastname: Lindahl
authors.forename: Matts
authors.initials: M
authors.lastname: Olovsson
authors.forename: Sigrid
authors.initials: S
authors.lastname: Nyberg
authors.forename: Kim
authors.initials: K
authors.lastname: Thorsen
authors.forename: Tommy
authors.initials: T
authors.lastname: Olsson
authors.forename: Inger
authors.initials: I
authors.lastname: Sundström Poromaa
mesh_terms: D000324:Adrenocorticotropic Hormone / Q000008:administration & dosage*; D000328:Adult; D000568:Amenorrhea / Q000097:blood* / Q000150:complications; D003430:Cross-Sectional Studies; D016207:Cytokines / Q000097:blood*; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000097:blood*; D007027:Hypothalamic Diseases / Q000097:blood* / Q000150:complications; D053577:Interleukin-1 Receptor Accessory Protein / Q000097:blood*; D008657:Metabolic Clearance Rate / Q000187:drug effects; D016896:Treatment Outcome
chemical_list: D016207:Cytokines; D053577:Interleukin-1 Receptor Accessory Protein; D000324:Adrenocorticotropic Hormone; D006854:Hydrocortisone